drugset

drugset / Trial / NCT06554509

Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis

NCT06554509 ↗

Phase 2/3 Recruiting 423 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.

Timeline

Start: 2024-09-19
Primary completion: 2028-10
Completion: 2028-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1819	Monoclonal antibody	—	—

Indications